Completed PHASE1 INTERVENTIONAL 4-arm NCT00660257

Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine

Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza (H5N1)Vaccine in Two-Dose Primed Healthy Adults: A Single Center, Non-Randomized Clinical Trial

Sponsor: Centers for Disease Control and Prevention, China

Conditions Pandemic Influenza Pandemic Influenza Vaccine Prevention

Interventions pandemic influenza vaccine (H5N1 strain NIBRG-14)

Updated 5 times since 2017 Last updated: Apr 16, 2008 Started: Jan 31, 2007 Primary completion: Mar 31, 2007 Completion: Mar 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00660257, this PHASE1 trial focuses on Pandemic Influenza and Pandemic Influenza Vaccine and remains completed. Sponsored by Centers for Disease Control and Prevention, China, it has been updated 5 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centers for Disease Control and Prevention, China
Sinovac Biotech Co., Ltd

Data source: Sinovac Biotech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China